Unraveling the ties between irritable bowel syndrome and intestinal microbiota

World Journal of Gastroenterology

Volumn 20, Issue 10, 2014, Pages 2470-2481

  Hong, Sung Noh ^a   Rhee, Poong Lyul ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Antibiotics; Dysbiosis; Intestinal microbiota; Irritable bowel syndrome; Probiotics

Indexed keywords

ANTIBIOTIC AGENT; BACTERIOCIN; CANNABINOID 2 RECEPTOR; CASPASE RECRUITMENT DOMAIN PROTEIN 15; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 8; MU OPIATE RECEPTOR; MUCIN; PROBIOTIC AGENT; RIFAXIMIN; SECRETORY IMMUNOGLOBULIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VSL3; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL OVERGROWTH; BACTEROIDES; BIFIDOBACTERIUM; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA MICROARRAY; DYSBIOSIS; FIRMICUTES; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; META ANALYSIS (TOPIC); METAGENOMICS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PREVOTELLA; PROTEIN EXPRESSION; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SYSTEMATIC REVIEW (TOPIC); ANIMAL; BACTERIA; CLASSIFICATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; INTESTINE; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; MICROFLORA; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; MICROBIOTA; PROBIOTICS; TREATMENT OUTCOME;

EID: 84896825642     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i10.2470     Document Type: Article

References (92)

1. Rhee PL. Definition and epidemiology of irritable bowel syndrome. Korean J Gastroenterol 2006; 47: 94-100 [PMID: 16498274]
2. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-2131 [PMID: 12454866 DOI: 10.1053/gast.2002.37095]
3. Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. Prevalence of irritable bowel syndrome: a community survey. Br J Gen Pract 2004; 54: 495-502 [PMID: 15239910]
4. Gwee KA, Wee S, Wong ML, Png DJ. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an asian urban community. Am J Gastroenterol 2004; 99: 924-931 [PMID: 15128362 DOI: 10.1111/j.1572-0241.2004.04161. x]
5. Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 1910-1915 [PMID: 12190153 DOI: 10.1111/j.1572-0241.2002.05913.x]
6. Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: a populationbased study. Am J Gastroenterol 2002; 97: 2290-2299 [PMID: 12358247 DOI: 10.1111/j.1572-0241.2002.05783.x]
7. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62: 159-176 [PMID: 22730468 DOI: 10.1136/ gutjnl-2012-302167]
8. Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, Kim YH, Kim JJ, Rhee JC, Rhee PL. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008; 53: 2714-2718 [PMID: 18274900 DOI: 10.1007/s10620-007-0196-4]
9. Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 2013; 29: 184-189 [PMID: 23286925 DOI: 10.1097/MOG.0b013e32835d7bba]
10. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-1988 [PMID: 19457422 DOI: 10.1053/j.gastro.2009.02.074]
11. Zoetendal EG, Rajilic-Stojanovic M, de Vos WM. Highthroughput diversity and functionality analysis of the gastrointestinal tract microbiota. Gut 2008; 57: 1605-1615 [PMID: 18941009 DOI: 10.1136/gut.2007.133603]
12. Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A, Petrosino JF, Highlander S, Gibbs R, Lynch SV, Shulman RJ, Versalovic J. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1782-1791 [PMID: 21741921 DOI: 10.1053/ j.gastro.2011.06.072]
13. Chassard C, Dapoigny M, Scott KP, Crouzet L, Del'homme C, Marquet P, Martin JC, Pickering G, Ardid D, Eschalier A, Dubray C, Flint HJ, Bernalier-Donadille A. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 2012; 35: 828-838 [PMID: 22315951 DOI: 10.1111/ j.1365-2036.2012.05007.x]
14. Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 521-530, e248 [PMID: 22339879 DOI: 10.1111/j.1365-2982.2012.01891.x]
15. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010; 156: 3205-3215 [PMID: 20705664 DOI: 10.1099/mic.0.043257-0]
16. Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 2008; 103: 1557-1567 [PMID: 18513268 DOI: 10.1111/ j.1572-0241.2008.01869.x]
17. Dethlefsen L, McFall-Ngai M, Relman DA. An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 2007; 449: 811-818 [PMID: 17943117 DOI: 10.1038/nature06245]
18. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65 [PMID: 20203603 DOI: 10.1038/nature08821]
19. Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, Clemente JC, Knight R, Heath AC, Leibel RL, Rosenbaum M, Gordon JI. The long-term stability of the human gut microbiota. Science 2013; 341: 1237439 [PMID: 23828941 DOI: 10.1126/science.1237439]
20. Koren O, Knights D, Gonzalez A, Waldron L, Segata N, Knight R, Huttenhower C, Ley RE. A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets. PLoS Comput Biol 2013; 9: e1002863 [PMID: 23326225 DOI: 10.1371/journal. pcbi.1002863]
21. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Doré J, Antolín M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo Minardi R, M'rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180 [PMID: 21508958 DOI: 10.1038/nature09944]
22. Claesson MJ, Cusack S, O'Sullivan O, Greene-Diniz R, de Weerd H, Flannery E, Marchesi JR, Falush D, Dinan T, Fitzgerald G, Stanton C, van Sinderen D, O'Connor M, Harnedy N, O'Connor K, Henry C, O'Mahony D, Fitzgerald AP, Shanahan F, Twomey C, Hill C, Ross RP, O'Toole PW. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4586-4591 [PMID: 20571116 DOI: 10.1073/ pnas.1000097107]
23. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334: 105-108 [PMID: 21885731 DOI: 10.1126/science.1208344]
24. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA 2010; 107: 14691-14696 [PMID: 20679230 DOI: 10.1073/pnas.1005963107]
25. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-484 [PMID: 19043404 DOI: 10.1038/nature07540]
26. Faith JJ, McNulty NP, Rey FE, Gordon JI. Predicting a human gut microbiota's response to diet in gnotobiotic mice. Science 2011; 333: 101-104 [PMID: 21596954 DOI: 10.1126/science. 1206025]
27. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 2005; 3: 442-448 [PMID: 15880313]
28. Bouhnik Y, Neut C, Raskine L, Michel C, Riottot M, Andrieux C, Guillemot F, Dyard F, Flourié B. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment Pharmacol Ther 2004; 19: 889-899 [PMID: 15080850 DOI: 10.1111/j.1365-2036.2004.01918.x]
29. Smith SC, Choy R, Johnson SK, Hall RS, Wildeboer-Veloo AC, Welling GW. Lupin kernel fiber consumption modifies fecal microbiota in healthy men as determined by rRNA gene fluorescent in situ hybridization. Eur J Nutr 2006; 45: 335-341 [PMID: 16763747 DOI: 10.1007/s00394-006-0603-1]
30. Ramnani P, Gaudier E, Bingham M, van Bruggen P, Tuohy KM, Gibson GR. Prebiotic effect of fruit and vegetable shots containing Jerusalem artichoke inulin: a human intervention study. Br J Nutr 2010; 104: 233-240 [PMID: 20187995 DOI: 10.1017/S000711451000036X]
31. Cloetens L, Broekaert WF, Delaedt Y, Ollevier F, Courtin CM, Delcour JA, Rutgeerts P, Verbeke K. Tolerance of arabinoxylan-oligosaccharides and their prebiotic activity in healthy subjects: a randomised, placebo-controlled crossover study. Br J Nutr 2010; 103: 703-713 [PMID: 20003568 DOI: 10.1017/S0007114509992248]
32. Nam YD, Jung MJ, Roh SW, Kim MS, Bae JW. Comparative analysis of Korean human gut microbiota by barcoded pyrosequencing. PLoS One 2011; 6: e22109 [PMID: 21829445 DOI: 10.1371/journal.pone.0022109]
33. Shanahan F. The colonic microbiota in health and disease. Curr Opin Gastroenterol 2013; 29: 49-54 [PMID: 23041677 DOI: 10.1097/MOG.0b013e32835a3493]
34. Sommer F, Bäckhed F. The gut microbiota--masters of host development and physiology. Nat Rev Microbiol 2013; 11: 227-238 [PMID: 23435359 DOI: 10.1038/nrmicro2974]
35. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature 2011; 474: 327-336 [PMID: 21677749 DOI: 10.1038/nature10213]
36. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5: 185-194 [PMID: 7121297]
37. Wyatt GM, Bayliss CE, Lakey AF, Bradley HK, Hunter JO, Jones VA. The faecal flora of two patients with food-related irritable bowel syndrome during challenge with symptomprovoking foods. J Med Microbiol 1988; 26: 295-299 [PMID: 3398034]
38. Hayashi H, Sakamoto M, Benno Y. Phylogenetic analysis of the human gut microbiota using 16S rDNA clone libraries and strictly anaerobic culture-based methods. Microbiol Immunol 2002; 46: 535-548 [PMID: 12363017]
39. Maccaferri S, Biagi E, Brigidi P. Metagenomics: key to human gut microbiota. Dig Dis 2011; 29: 525-530 [PMID: 22179207 DOI: 10.1159/000332966]
40. Woese CR, Fox GE. Phylogenetic structure of the prokaryotic domain: the primary kingdoms. Proc Natl Acad Sci USA 1977; 74: 5088-5090 [PMID: 270744]
41. Nocker A, Burr M, Camper AK. Genotypic microbial community profiling: a critical technical review. Microb Ecol 2007; 54: 276-289 [PMID: 17345133 DOI: 10.1007/ s00248-006-9199-5]
42. Roh SW, Abell GC, Kim KH, Nam YD, Bae JW. Comparing microarrays and next-generation sequencing technologies for microbial ecology research. Trends Biotechnol 2010; 28: 291-299 [PMID: 20381183 DOI: 10.1016/j.tibtech.2010.03.001]
43. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33 [PMID: 17631127 DOI: 10.1053/ j.gastro.2007.04.005]
44. Deplancke B, Gaskins HR. Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. Am J Clin Nutr 2001; 73: 1131S-1141S [PMID: 11393191]
45. Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792-1801 [PMID: 21820992 DOI: 10.1053/ j.gastro.2011.07.043]
46. Mättö J, Maunuksela L, Kajander K, Palva A, Korpela R, Kassinen A, Saarela M. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome--a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005; 43: 213-222 [PMID: 15747442]
47. Swidsinski A, Sydora BC, Doerffel Y, Loening-Baucke V, Vaneechoutte M, Lupicki M, Scholze J, Lochs H, Dieleman LA. Viscosity gradient within the mucus layer determines the mucosal barrier function and the spatial organization of the intestinal microbiota. Inflamm Bowel Dis 2007; 13: 963-970 [PMID: 17455202 DOI: 10.1002/ibd.20163]
48. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106: 329-336 [PMID: 21102570 DOI: 10.1038/ajg.2010.438]
49. Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, Campieri M, Kamm MA, Knight SC, Stagg AJ. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004; 53: 1602-1609 [PMID: 15479680 DOI: 10.1136/gut.2003.037325]
50. López P, González-Rodríguez I, Gueimonde M, Margolles A, Suárez A. Immune response to Bifidobacterium bifidum strains support Treg/Th17 plasticity. PLoS One 2011; 6: e24776 [PMID: 21966367 DOI: 10.1371/journal.pone.0024776]
51. Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Packey CD, Sartor RB, Ringel Y. Molecular analysis of the luminaland mucosal-associated intestinal microbiota in diarrheapredominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2011; 301: G799-G807 [PMID: 21737778 DOI: 10.1152/ajpgi.00154.2011]
52. Parkes GC, Rayment NB, Hudspith BN, Petrovska L, Lomer MC, Brostoff J, Whelan K, Sanderson JD. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 31-39 [PMID: 22070725 DOI: 10.1111/ j.1365-2982.2011.01803.x]
53. Verdú EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W, Mao Y, Wang L, Rochat F, Collins SM. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006; 55: 182-190 [PMID: 16105890 DOI: 10.1136/gut.2005.066100]
54. Kamm K, Hoppe S, Breves G, Schröder B, Schemann M. Effects of the probiotic yeast Saccharomyces boulardii on the neurochemistry of myenteric neurones in pig jejunum. Neurogastroenterol Motil 2004; 16: 53-60 [PMID: 14764205 DOI: 10.1046/j.1365-2982.2003.00458.x]
55. Collins SM. Dysregulation of peripheral cytokine production in irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2517-2518 [PMID: 16279908 DOI: 10.1111/ j.1572-0241.2005.00246.x]
56. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551 [PMID: 15765388]
57. Lamine F, Fioramonti J, Bueno L, Nepveu F, Cauquil E, Lobysheva I, Eutamène H, Théodorou V. Nitric oxide released by Lactobacillus farciminis improves TNBS-induced colitis in rats. Scand J Gastroenterol 2004; 39: 37-45 [PMID: 14992560 DOI: 10.1080/00365520310007152]
58. Ait-Belgnaoui A, Han W, Lamine F, Eutamene H, Fioramonti J, Bueno L, Theodorou V. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 2006; 55: 1090-1094 [DOI: 10.1136/gut.2005.084194]
59. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35-37 [PMID: 17159985 DOI: 10.1038/nm1521]
60. Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett P, Macri J, McCoy KD, Verdu EF, Collins SM. The intestinal microbiota affect central levels of brainderived neurotropic factor and behavior in mice. Gastroenterology 2011; 141: 599-609, 609. e1-3 [PMID: 21683077 DOI: 10.1053/j.gastro.2011.04.052]
61. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-3506 [PMID: 11151884 DOI: 10.1111/j.1572-0241.2000.03368.x]
62. Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol 2011; 9: 461-49; quiz e59 [PMID: 21397724 DOI: 10.1016/j.cgh.2011.02.030]
63. Simrén M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut 2006; 55: 297-303 [PMID: 16474100 DOI: 10.1136/ gut.2005.075127]
64. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 1279-1286 [PMID: 19602448 DOI: 10.1016/ j.cgh.2009.06.031]
65. Quigley EM. Antibiotics for irritable bowel syndrome: hitting the target, but what is it? Gastroenterology 2011; 141: 391-393 [PMID: 21620844 DOI: 10.1053/j.gastro.2011.05.014]
66. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebocontrolled study. Am J Gastroenterol 2003; 98: 412-419 [PMID: 12591062 DOI: 10.1111/j.1572-0241.2003.07234.x]
67. Esposito I, de Leone A, Di Gregorio G, Giaquinto S, de Magistris L, Ferrieri A, Riegler G. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol 2007; 13: 6016-6021 [PMID: 18023092]
68. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145: 557-563 [PMID: 17043337]
69. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32 [PMID: 21208106 DOI: 10.1056/NEJMoa1004409]
70. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 28-35; quiz 36 [PMID: 22045120 DOI: 10.1038/ajg.2011.355]
71. Sibartie S, O'Hara AM, Ryan J, Fanning A, O'Mahony J, O' Neill S, Sheil B, O'Mahony L, Shanahan F. Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria. BMC Immunol 2009; 10: 54 [PMID: 19814810 DOI: 10.1186/1471-2172-10-54]
72. Kekkonen RA, Lummela N, Karjalainen H, Latvala S, Tynkkynen S, Jarvenpaa S, Kautiainen H, Julkunen I, Vapaatalo H, Korpela R. Probiotic intervention has strain-specific antiinflammatory effects in healthy adults. World J Gastroenterol 2008; 14: 2029-2036 [PMID: 18395902]
73. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14: 2650-2661 [PMID: 18461650]
74. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9: 15 [PMID: 19220890 DOI: 10.1186/1471-230X-9-15]
75. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-332 [PMID: 19091823 DOI: 10.1136/ gut.2008.167270]
76. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033-1049; quiz 1050 [PMID: 19277023 DOI: 10.1038/ ajg.2009.25]
77. Ortiz-Lucas M, Tobías A, Saz P, Sebastián JJ. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Rev Esp Enferm Dig 2013; 105: 19-36 [PMID: 23548007]
78. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-1147 [PMID: 11711768]
79. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895-904 [PMID: 12656692]
80. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687-696 [PMID: 16185307 DOI: 10.1111/j.1365-2982.2005.00695.x]
81. Kekkonen RA, Kajasto E, Miettinen M, Veckman V, Korpela R, Julkunen I. Probiotic Leuconostoc mesenteroides ssp. cremoris and Streptococcus thermophilus induce IL-12 and IFN-gamma production. World J Gastroenterol 2008; 14: 1192-1203 [PMID: 18300344]
82. Choi SC, Kim BJ, Rhee PL, Chang DK, Son HJ, Kim JJ, Rhee JC, Kim SI, Han YS, Sim KH, Park SN. Probiotic Fermented Milk Containing Dietary Fiber Has Additive Effects in IBS with Constipation Compared to Plain Probiotic Fermented Milk. Gut Liver 2011; 5: 22-28 [PMID: 21461068 DOI: 10.5009/ gnl.2011.5.1.22]
83. Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373-382 [PMID: 15667495 DOI: 10.1111/ j.1572-0241.2005.40312.x]
84. Maukonen J, Satokari R, Mättö J, Söderlund H, Mattila-Sandholm T, Saarela M. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 2006; 55: 625-633 [PMID: 16585652 DOI: 10.1099/jmm.0.46134-0]
85. Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K, Akkermans LM. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15: 2887-2892 [PMID: 19533811]
86. Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L, Mäkivuokko H, Kajander K, Palva A. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009; 9: 95 [PMID: 20015409 DOI: 10.1186/1471-230X-9-95]
87. Lyra A, Rinttilä T, Nikkilä J, Krogius-Kurikka L, Kajander K, Malinen E, Mättö J, Mäkelä L, Palva A. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 2009; 15: 5936-5945 [PMID: 20014457]
88. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 512-519, e114-e115 [PMID: 19903265]
89. Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010; 55: 392-397 [PMID: 19693670]
90. Ponnusamy K, Choi JN, Kim J, Lee SY, Lee CH. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol 2011; 60: 817-827 [PMID: 21330412]
91. Rinttilä T, Lyra A, Krogius-Kurikka L, Palva A. Real-time PCR analysis of enteric pathogens from fecal samples of irritable bowel syndrome subjects. Gut Pathog 2011; 3: 6 [PMID: 21518462]
92. Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997-1006 [PMID: 22180058]